NSAIDs are mostly known as cyclooxygenase inhibitors, preventing prostaglandin and thromboxane synthesis from arachidonic acid, but additional cyclooxygenase-unrelated activities, such as binding to prostaglandin receptors, modulation of γ-secretase activity and activation of the peroxisomal proliferator receptor γ (PPARγ), a member of the nuclear hormone receptor superfamily, seem to be involved in AD prevention. Here, PPARG is linked to Alzheimer disease.